Raymond James & Associates Boosts Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Raymond James & Associates lifted its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 128.5% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 91,985 shares of the medical device company's stock after buying an additional 51,721 shares during the quarter. Raymond James & Associates owned about 0.14% of Tandem Diabetes Care worth $2,721,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. raised its stake in Tandem Diabetes Care by 40.5% in the first quarter. JPMorgan Chase & Co. now owns 133,397 shares of the medical device company's stock valued at $15,512,000 after purchasing an additional 38,460 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Tandem Diabetes Care by 2.7% in the first quarter. PNC Financial Services Group Inc. now owns 6,246 shares of the medical device company's stock valued at $726,000 after acquiring an additional 164 shares during the last quarter. Great West Life Assurance Co. Can grew its position in Tandem Diabetes Care by 7.5% in the first quarter. Great West Life Assurance Co. Can now owns 34,482 shares of the medical device company's stock valued at $4,122,000 after acquiring an additional 2,402 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Tandem Diabetes Care by 68.5% in the first quarter. Dimensional Fund Advisors LP now owns 185,408 shares of the medical device company's stock valued at $21,561,000 after acquiring an additional 75,358 shares during the last quarter. Finally, Canada Pension Plan Investment Board grew its position in Tandem Diabetes Care by 3.4% in the first quarter. Canada Pension Plan Investment Board now owns 5,616 shares of the medical device company's stock valued at $654,000 after acquiring an additional 184 shares during the last quarter.

Tandem Diabetes Care Trading Down 4.9 %

Shares of Tandem Diabetes Care stock traded down $1.64 during midday trading on Monday, reaching $31.86. The company had a trading volume of 1,055,497 shares, compared to its average volume of 1,773,229. Tandem Diabetes Care, Inc. has a fifty-two week low of $13.82 and a fifty-two week high of $42.09. The company has a debt-to-equity ratio of 0.91, a current ratio of 3.83 and a quick ratio of 3.02. The stock has a fifty day moving average price of $29.30 and a 200 day moving average price of $24.62. The firm has a market cap of $2.06 billion, a PE ratio of -9.26 and a beta of 1.11.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. The business had revenue of $196.80 million during the quarter, compared to analyst estimates of $204.86 million. On average, equities analysts anticipate that Tandem Diabetes Care, Inc. will post -1.62 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Citigroup lifted their target price on Tandem Diabetes Care from $31.00 to $38.00 and gave the company a "neutral" rating in a research report on Wednesday, April 3rd. StockNews.com cut Tandem Diabetes Care from a "hold" rating to a "sell" rating in a research report on Thursday. Finally, Stifel Nicolaus upgraded Tandem Diabetes Care from a "hold" rating to a "buy" rating and lifted their target price for the company from $24.00 to $37.00 in a research report on Tuesday, March 26th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Tandem Diabetes Care has an average rating of "Hold" and an average price target of $37.00.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.